MX389926B - Formulaciones de fenilacetato de l-ornitina - Google Patents
Formulaciones de fenilacetato de l-ornitinaInfo
- Publication number
- MX389926B MX389926B MX2018005088A MX2018005088A MX389926B MX 389926 B MX389926 B MX 389926B MX 2018005088 A MX2018005088 A MX 2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A MX 389926 B MX389926 B MX 389926B
- Authority
- MX
- Mexico
- Prior art keywords
- ornithine phenylacetate
- formulations
- patients
- oral formulations
- acute
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255300P | 2015-11-13 | 2015-11-13 | |
| US201662276754P | 2016-01-08 | 2016-01-08 | |
| US15/133,087 US20160338982A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
| PCT/US2016/061678 WO2017083758A1 (en) | 2015-11-13 | 2016-11-11 | Formulation of l-ornithine phenylacetate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005088A MX2018005088A (es) | 2019-05-16 |
| MX389926B true MX389926B (es) | 2025-03-20 |
Family
ID=58695607
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005088A MX389926B (es) | 2015-11-13 | 2016-11-11 | Formulaciones de fenilacetato de l-ornitina |
| MX2022001517A MX2022001517A (es) | 2015-11-13 | 2018-04-25 | Formulaciones de fenilacetato de l-ornitina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001517A MX2022001517A (es) | 2015-11-13 | 2018-04-25 | Formulaciones de fenilacetato de l-ornitina. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3373923A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7294807B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20180086431A (cg-RX-API-DMAC7.html) |
| CN (2) | CN108366983A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016353350B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018009349A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3004331A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL258630B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX389926B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018113801A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201802987UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017083758A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| BR112020002419A2 (pt) | 2017-08-14 | 2020-07-28 | Axcella Health Inc. | aminoácido para o tratamento de doença do fígado |
| CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
| PH12022550738A1 (en) * | 2019-10-16 | 2023-05-08 | Mallinckrodt Entpr Llc | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| MX2007006171A (es) * | 2004-11-26 | 2007-10-08 | Ucl Business Plc | Composiciones que comprenden ornitina y acetato. |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| EP3263100B1 (en) * | 2009-04-03 | 2020-04-01 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| AU2015221466B2 (en) * | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| KR101715008B1 (ko) * | 2009-06-08 | 2017-03-22 | 유씨엘 비즈니스 피엘씨 | Ｌ―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복 |
| AU2014250643B2 (en) * | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| EP2625162B1 (en) * | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| CN103705490B (zh) * | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
| CA2968544A1 (en) * | 2014-11-24 | 2016-06-02 | Ucl Business Plc | Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies |
| CA2983146C (en) * | 2015-04-20 | 2023-09-12 | Ocera Therapeutics, Inc. | Formulations of l-ornithine phenylacetate |
| EP3337473A4 (en) * | 2015-08-18 | 2019-04-17 | Ocera Therapeutics, Inc. | TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE |
| CA2998490A1 (en) * | 2015-09-25 | 2017-03-30 | Ocera Therapeutics, Inc. | Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
-
2016
- 2016-11-11 BR BR112018009349A patent/BR112018009349A8/pt not_active Application Discontinuation
- 2016-11-11 KR KR1020187016373A patent/KR20180086431A/ko not_active Ceased
- 2016-11-11 MX MX2018005088A patent/MX389926B/es unknown
- 2016-11-11 JP JP2018524369A patent/JP7294807B2/ja active Active
- 2016-11-11 EP EP16865158.6A patent/EP3373923A4/en not_active Withdrawn
- 2016-11-11 WO PCT/US2016/061678 patent/WO2017083758A1/en not_active Ceased
- 2016-11-11 CN CN201680066488.5A patent/CN108366983A/zh active Pending
- 2016-11-11 CN CN202111062923.6A patent/CN113768863A/zh active Pending
- 2016-11-11 KR KR1020247042587A patent/KR20250023993A/ko active Pending
- 2016-11-11 SG SG11201802987UA patent/SG11201802987UA/en unknown
- 2016-11-11 CA CA3004331A patent/CA3004331A1/en not_active Abandoned
- 2016-11-11 RU RU2018113801A patent/RU2018113801A/ru not_active Application Discontinuation
- 2016-11-11 AU AU2016353350A patent/AU2016353350B2/en not_active Ceased
-
2018
- 2018-04-11 IL IL258630A patent/IL258630B2/en unknown
- 2018-04-25 MX MX2022001517A patent/MX2022001517A/es unknown
-
2021
- 2021-12-21 AU AU2021290236A patent/AU2021290236A1/en not_active Abandoned
- 2021-12-28 JP JP2021213640A patent/JP2022058446A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018533601A (ja) | 2018-11-15 |
| MX2022001517A (es) | 2022-11-16 |
| IL258630B2 (en) | 2023-08-01 |
| CN108366983A (zh) | 2018-08-03 |
| KR20250023993A (ko) | 2025-02-18 |
| IL258630B1 (en) | 2023-04-01 |
| EP3373923A4 (en) | 2019-07-03 |
| KR20180086431A (ko) | 2018-07-31 |
| AU2021290236A1 (en) | 2022-02-10 |
| JP7294807B2 (ja) | 2023-06-20 |
| CA3004331A1 (en) | 2017-05-18 |
| EP3373923A1 (en) | 2018-09-19 |
| IL258630A (en) | 2018-06-28 |
| BR112018009349A8 (pt) | 2019-02-26 |
| RU2018113801A (ru) | 2019-12-16 |
| AU2016353350A1 (en) | 2018-05-10 |
| AU2016353350B2 (en) | 2021-09-23 |
| MX2018005088A (es) | 2019-05-16 |
| WO2017083758A1 (en) | 2017-05-18 |
| BR112018009349A2 (pt) | 2018-11-13 |
| SG11201802987UA (en) | 2018-05-30 |
| JP2022058446A (ja) | 2022-04-12 |
| CN113768863A (zh) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013170A (es) | Formulaciones de fenilacetato de l-ornitina. | |
| MX2022001517A (es) | Formulaciones de fenilacetato de l-ornitina. | |
| CO2019006291A2 (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
| CL2018002334A1 (es) | Moduladores de complementos factor b (divisional solicitud 201600606) | |
| MA42950A (fr) | Administration d'agents de potentialisation de cftr modifiés au deutérium | |
| MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| MX2018002990A (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos. | |
| MX2017015236A (es) | Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation. | |
| BR112015030514A2 (pt) | Composições e métodos para conjugação de anticorpos ativáveis | |
| UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
| BR112015017251A2 (pt) | composições farmacêuticas compreendendo doadores de nitroxil | |
| BR112016016274A2 (pt) | Ponte da barreira hematoencefálica | |
| BR112019003577A2 (pt) | métodos de tratamento da semente e produtos resultantes | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| BR112015023387A2 (pt) | composições lipídicas de racecodotril | |
| BR112017004745A2 (pt) | adição a um aplicador médico | |
| MX2017000676A (es) | Oritavancina de alta pureza y metodo para producir la misma. | |
| BR112017021353A2 (pt) | conexão de orifício estéril | |
| BR112016028518A2 (pt) | composições farmacêuticas que compreendem dgla e uso do mesmo | |
| MX2017009325A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| AR100028A1 (es) | Composiciones nutricionales que contienen ácido estearidónico | |
| MX2018015965A (es) | Composicion de dos componentes. | |
| BR112015022940A2 (pt) | composições líquidas de racecadotrila |